GSK's Linerixibat Granted Priority Review in China for Cholestatic Pruritus in PBC

summarizeSummary

GSK announced that its new drug application for linerixibat, targeting cholestatic pruritus in primary biliary cholangitis (PBC), has been accepted for priority review by China's National Medical Products Administration.

check_boxKey Events

• Priority Review Granted in China

  Linerixibat, an investigational drug for cholestatic pruritus in primary biliary cholangitis (PBC), has been accepted for priority review by China's National Medical Products Administration.

• Addresses Significant Unmet Need

  Cholestatic pruritus in PBC is a serious and debilitating condition affecting approximately 280,000 people in China, with few effective treatment options.

• Based on Positive Phase III Data

  The application is supported by positive data from the GLISTEN phase III trial, which demonstrated significant and sustained improvement in pruritus and sleep interference.

• Global Regulatory Progress

  Marketing applications for linerixibat are also currently under Health Authority review in the US, EU, UK, and Canada, with Orphan Drug Designation already granted in the US, EU, and Japan.

auto_awesomeAnalysis

GSK's investigational drug, linerixibat, receiving priority review in China is a significant positive development. This accelerates the regulatory pathway in a substantial market, as China has a large patient population suffering from primary biliary cholangitis (PBC) and associated cholestatic pruritus, a debilitating condition with limited treatment options. The priority review status, based on positive Phase III trial data, indicates regulatory confidence and brings the drug closer to potential commercialization. This milestone, alongside ongoing reviews in other major markets, strengthens GSK's hepatology pipeline and could contribute meaningfully to future revenue, especially as the company's stock is currently trading near its 52-week high.